Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Brands targeted as acquisition candidates likely would be $10 mil.-$50 mil. businesses in the OTC category that are advertising sensitive, Chattem notes during Deutsche Bank Securities Small Cap Growth Conference Feb. 16. The firm states it would stay out of "huge categories with a lot of bigger players." Acquisitions, however, are not a priority for Chattem, as it currently is more interested in licensing new technology for use in skin care and pain relief than buying standalone brands (1"The Tan Sheet" Feb. 6, 2006, p. 6)...

You may also be interested in...

Chattem Looks To Tech: ‘Cool’ New Products Not What They Used To Be

Chattem is focused on acquiring technology rather than new brands, the firm said during a report on fourth-quarter and fiscal year 2005 (ended Nov. 30)

Health And Wellness Trademark Review 18 February, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts